Immuneering - Class A (IMRX) closed at $3.79 on November 11, 2026, down 1.6% from the previous close, on volume of 435,202 shares (30-day average 748,102).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Immuneering Appoints Grant C. Bogle to Board of Directors
TipRanks (Mon, 9-Nov 5:34 PM ET)
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
Globe Newswire (Mon, 9-Nov 7:30 AM ET)
H.C. Wainwright Reaffirms Their Buy Rating on Immuneering (IMRX)
TipRanks (Mon, 9-Nov 6:35 AM ET)
Globe Newswire (Fri, 6-Nov 9:00 AM ET)
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Globe Newswire (Wed, 4-Nov 7:30 AM ET)
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Thu, 29-Oct 4:05 PM ET)
Globe Newswire (Mon, 26-Oct 7:30 AM ET)
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Globe Newswire (Fri, 2-Oct 9:00 AM ET)
Globe Newswire (Mon, 28-Sep 7:30 AM ET)
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Immuneering - Class A trades on the NASDAQ stock market under the symbol IMRX.
As of November 11, 2026, IMRX stock price declined to $3.79 with 435,202 million shares trading.
IMRX has a beta of 0.89, meaning it tends to be less sensitive to market movements. IMRX has a correlation of 0.02 to the broad based SPY ETF.
IMRX has a market cap of $245.45 million. This is considered a Small Cap stock.
In the last 3 years, IMRX traded as high as $10.08 and as low as $1.00.
The top ETF exchange traded funds that IMRX belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
IMRX has underperformed the market in the last year with a return of -45.2%, while the SPY ETF gained +12.6%. In the last 3 month period, IMRX fell short of the market, returning -16.3%, while SPY returned -1.5%. However, in the most recent 2 weeks IMRX has outperformed the stock market by returning -1.0%, while SPY returned -1.3%.
IMRX support price is $3.67 and resistance is $4.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMRX shares will trade within this expected range on the day.
